Skip to main content

Table 2 Demographic and clinical characteristics of patients during the trial

From: Impact of daily supplementation of Spirulina platensis on the immune system of naïve HIV-1 patients in Cameroon: a 12-months single blind, randomized, multicenter trial

Variables Ctrl/Spi Period Patients received local balance diet Patients received spirulina combined with a local balance diet p-value
Age (Years) 87/82 T0 35.43 ± 10.04 36.01 ± 9.44 0.58
Sex (%)      
Female 87/82 T0 64.5 % (56) 69.8 % (60) 0.06
Male 35.6 % (31) 25.6 % (22)
BMI (kg/m2) 87/82 T0 26.02 ± 4.97 25.29 ± 4.54 0 .33
79/80 T6 25.18 ± 6.41 25.41 ± 4.98 0.80
66 /79 T12 22.18 ± 1.07 23.26 ± 6.53 0.44
CD4 (cells/μL) 87/82 T0 569.40 ± 179.89 596.32 ± 198 0.36
79/80 T6 464.86 ± 200.33 609.07 ± 149.14 <0.00*
66/79 T12 429.04 ± 177.19 614.92 ± 179.43 <0.00*
Viral load (copies/mL) 87/82 T0 61199.03 ± 6.27 74770.33 ± 3.19 0.53
79/80 T6 66615,45 ± 7.45 38539.70 ± 2.22 <0.00
66/79 T12 174595.22 ± 1.20 30872.33 ± 3.93 <0.00
Hemoglobin (mg/dL) 87/82 T0 12.87 ± 1.53 13.14 ± 1.85 0.32
79/80 T6 12.22 ± 1.42 13.49 ± 1.24 <0.00
66/79 T12 11.69 ± 1.62 12.71 ± 1.71 <0.00
Fasting Blood Sugar (mg/L) 87/82 T0 115 ± 53.70 105.89 ± 25.91 0.159
79/80 T6 105.00 ± 30.76 103.14 ± 15.93 0.65
66 /79 T12 113.77 ± 61.85 95.35 ± 9.63 <0.00*
  1. Mean values ± SD. *Significant difference between the group (P < 0.00). Significant difference between the group (p < 0.05). Ctrl: Control, Spi: Spirulina group; To, T6,T13: time (months)